From Early Intervention to Holistic Care: ATTR-CM Updates From ACC 2026

Drs. Alexander and Witteles discuss emerging data on transthyretin amyloid cardiomyopathy therapies, emphasizing early initiation of disease-modifying treatment and the prognostic value of functional measures such as the six-minute walk test. They also highlight observational evidence that aggressive cardiometabolic management, including use of newer antidiabetic agents, may further reduce residual cardiovascular risk in patients with ATTR-CM and diabetes.